XBIT net incomeQ2 2026-$6.73M
XBIT net income was -$6.73M in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$1.76M a year earlier. For the full fiscal 2025 it was -$45.54M, compared with -$38.53M in fiscal 2024.
XBiotech Inc. (XBIT) financials
For the twelve months ended Jun 30, 2026, XBiotech Inc. reported -$45.13M of net income.
- Net income, TTM
- -$45.13M
- Free cash flow, TTM
- -$40.84M
- Cash
- $109.53M
- Market cap
- $58.2M
FY2018FY2023
FY2016FY2025
FY2016FY2025
XBIT revenue and earnings growth
XBIT EPSFY2025-$1.49
XBIT diluted EPS was -$1.49 for fiscal 2025 (ended Dec 31, 2025), compared with -$1.26 in fiscal 2024.
XBIT free cash flowQ2 2026-$4.51M
XBIT free cash flow was -$4.51M in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$6.04M a year earlier. For the full fiscal 2025 it was -$40.21M, compared with -$32.27M in fiscal 2024.
Income statement
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | $0 | $4.01M | $18.39M | $44.00M | $0 | $0 | - | - |
| Cost of revenue | - | - | $0 | $651.0K | $5.82M | $34.55M | $0 | $0 | - | - |
| Gross profit | - | - | $0 | $3.36M | $12.57M | $9.45M | $0 | $0 | - | - |
| Research and development | $47.39M | $37.76M | $32.85M | $31.54M | $28.27M | $9.53M | $24.09M | $15.72M | $26.42M | $42.49M |
| Selling, general and admin | $8.29M | $4.71M | $4.66M | $6.30M | $9.39M | $18.20M | $7.14M | $5.27M | $7.63M | $10.28M |
| Operating income | -$55.69M | -$42.47M | -$37.51M | -$34.49M | -$25.08M | -$18.28M | -$31.23M | -$20.99M | -$34.06M | -$52.76M |
| Pre-tax income | -$45.30M | -$38.56M | -$24.31M | -$33.59M | -$25.46M | -$12.83M | $718.45M | -$21.14M | -$33.15M | -$52.76M |
| Income tax | $235.0K | -$32.0K | $244.0K | -$688.0K | -$8.04M | -$1.61M | $49.82M | $0 | $0 | $0 |
| Net income | -$45.54M | -$38.53M | -$24.56M | -$32.90M | -$17.41M | -$11.22M | $668.63M | -$21.14M | -$33.15M | -$52.76M |
| EPS, basic | -$1.49 | -$1.26 | -$0.81 | -$1.08 | -$0.58 | -$0.36 | $17.17 | -$0.59 | -$0.95 | -$1.63 |
| EPS, diluted | -$1.49 | -$1.26 | -$0.81 | -$1.08 | -$0.58 | -$0.36 | $14.44 | -$0.59 | -$0.95 | -$1.63 |
| Diluted shares | 30.5M | 30.5M | 30.4M | 30.4M | 30.0M | 30.8M | 46.3M | 35.8M | 34.9M | 32.4M |
Balance sheet
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $125.55M | $172.68M | $200.02M | $157.31M | $236.98M | $237.37M | $714.59M | $15.82M | $31.77M | $34.32M |
| Short-term investments | - | - | $0 | $60.17M | $0 | - | - | - | - | - |
| Receivables | - | $700.0K | $860.0K | $1.22M | $0 | $4.11M | $0 | - | - | - |
| Current assets | $126.95M | $174.57M | $201.72M | $219.84M | $246.87M | $325.88M | $716.26M | $17.02M | $33.33M | $36.93M |
| Total assets | $150.08M | $199.09M | $226.62M | $246.10M | $275.18M | $353.74M | $816.88M | $44.34M | $62.97M | $67.05M |
| Current liabilities | $7.93M | $15.11M | $6.10M | $4.07M | $3.45M | $3.98M | $60.19M | $2.94M | $2.79M | $7.96M |
| Total liabilities | $9.73M | $16.82M | $7.77M | $5.70M | $5.79M | $5.11M | $61.25M | $2.95M | $2.81M | $7.99M |
| Shareholders' equity | $140.35M | $182.27M | $218.85M | $240.40M | $269.38M | $348.64M | $755.63M | $41.40M | $60.16M | $59.06M |
Cash flow
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$39.92M | -$30.96M | -$18.73M | -$14.82M | $69.44M | -$65.15M | -$18.27M | -$16.54M | -$33.65M | -$46.02M |
| Capital expenditures | $289.0K | $1.30M | $362.0K | $585.0K | $3.52M | $3.73M | $204.0K | $122.0K | $1.41M | $4.75M |
| Free cash flow | -$40.21M | -$32.27M | -$19.09M | -$15.41M | $65.92M | -$68.88M | -$18.47M | -$16.66M | -$35.05M | -$50.76M |
| Investing cash flow | -$289.0K | -$1.30M | $61.50M | -$63.89M | -$3.52M | -$3.73M | $674.80M | -$122.0K | -$1.41M | -$13.91M |
| Financing cash flow | -$10.25M | $10.45M | -$9.0K | $0 | -$67.01M | -$409.72M | $42.10M | $201.0K | $33.32M | $2.94M |
| Dividends paid | - | - | - | $0 | $75.00M | $0 | $0 | - | - | - |
| Share repurchases | - | $0 | $14.0K | $0 | - | - | - | - | - | - |
| Stock-based compensation | $3.62M | $1.75M | $3.26M | $5.06M | $4.46M | $12.58M | $3.36M | $1.66M | $1.75M | $5.57M |
Key ratios
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth, YoY | - | - | -100.0% | -78.2% | -58.2% | - | - | - | - | - |
| Gross margin | - | - | - | 83.8% | 68.4% | 21.5% | - | - | - | - |
| Operating margin | - | - | - | -860.1% | -136.4% | -41.5% | - | - | - | - |
| Net margin | - | - | - | -820.4% | -94.7% | -25.5% | - | - | - | - |
| Free cash flow margin | - | - | - | -384.3% | 358.4% | -156.5% | - | - | - | - |
| Return on equity | -32.4% | -21.1% | -11.2% | -13.7% | -6.5% | -3.2% | 88.5% | -51.1% | -55.1% | -89.3% |
| Return on assets | -30.3% | -19.4% | -10.8% | -13.4% | -6.3% | -3.2% | 81.9% | -47.7% | -52.6% | -78.7% |
| Current ratio | 16.01 | 11.56 | 33.07 | 54.07 | 71.49 | 81.80 | 11.90 | 5.78 | 11.94 | 4.64 |
Income statement
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | $0 | $0 |
| Cost of revenue | - | - | - | - | - | - | - | - | - | - | $0 | $0 |
| Gross profit | - | - | - | - | - | - | - | - | - | - | $0 | $0 |
| Research and development | $5.30M | $5.21M | $25.36M | $5.08M | $5.34M | $11.62M | $7.82M | $7.13M | $12.98M | $9.82M | $7.80M | $7.55M |
| Selling, general and admin | $850.0K | $1.07M | $4.40M | $967.0K | $1.00M | $1.93M | $927.0K | $777.0K | $1.98M | $1.03M | $783.0K | $973.0K |
| Operating income | -$6.15M | -$6.27M | -$29.75M | -$6.05M | -$6.34M | -$13.55M | -$8.75M | -$7.90M | -$14.97M | -$10.85M | -$8.59M | -$8.52M |
| Pre-tax income | -$6.68M | -$5.46M | -$26.82M | -$5.91M | -$1.73M | -$10.86M | -$10.55M | -$5.01M | -$13.03M | -$9.98M | -$4.73M | -$7.06M |
| Income tax | $46.0K | $49.0K | $76.0K | $102.0K | $28.0K | $29.0K | -$41.0K | $9.0K | -$25.0K | $25.0K | -$99.0K | $308.0K |
| Net income | -$6.73M | -$5.50M | -$26.89M | -$6.01M | -$1.76M | -$10.88M | -$10.51M | -$5.01M | -$13.01M | -$10.00M | -$4.63M | -$7.36M |
| EPS, basic | -$0.22 | -$0.18 | - | -$0.20 | -$0.06 | -$0.36 | - | -$0.16 | -$0.43 | -$0.33 | -$0.15 | -$0.24 |
Balance sheet
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $109.53M | $115.46M | $125.55M | $147.37M | $152.94M | $155.90M | $172.68M | $183.12M | $188.53M | $201.04M | $200.02M | $202.19M |
| Short-term investments | - | - | - | - | - | - | - | - | - | - | $0 | $0 |
| Receivables | - | - | - | $450.0K | $480.0K | $480.0K | $700.0K | $730.0K | $870.0K | $870.0K | $860.0K | $881.0K |
| Current assets | $111.16M | $117.05M | $126.95M | $148.95M | $154.89M | $157.69M | $174.57M | $185.03M | $190.64M | $203.06M | $201.72M | $204.40M |
| Total assets | $133.65M | $139.84M | $150.08M | $172.42M | $178.68M | $181.86M | $199.09M | $209.85M | $215.56M | $227.86M | $226.62M | $229.60M |
| Current liabilities | $3.35M | $3.00M | $7.93M | $3.56M | $3.86M | $5.41M | $15.11M | $15.99M | $17.14M | $16.88M | $6.10M | $5.29M |
| Total liabilities | $5.19M | $4.82M | $9.73M | $5.34M | $5.62M | $7.15M | $16.82M | $17.74M | $18.85M | $18.58M | $7.77M | $6.94M |
| Shareholders' equity | $128.46M | $135.02M | $140.35M | $167.08M | $173.06M | $174.71M | $182.27M | $192.12M | $196.70M | $209.28M | $218.85M | $222.66M |
Cash flow
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$4.51M | -$8.97M | -$22.95M | -$4.26M | -$5.99M | -$6.72M | -$6.54M | -$5.84M | -$11.38M | -$7.20M | -$3.43M | -$1.49M |
| Capital expenditures | $0 | $0 | $34.0K | $110.0K | $51.0K | $94.0K | $84.0K | $338.0K | $627.0K | $255.0K | $115.0K | $33.0K |
| Free cash flow | -$4.51M | -$8.97M | -$22.99M | -$4.37M | -$6.04M | -$6.81M | -$6.62M | -$6.18M | -$12.00M | -$7.46M | -$3.55M | -$1.52M |
| Investing cash flow | -$4.0K | $9.0K | -$34.0K | -$110.0K | -$51.0K | -$94.0K | -$84.0K | -$338.0K | -$627.0K | -$255.0K | -$115.0K | $61.83M |
| Financing cash flow | $0 | $0 | $0 | $0 | $0 | -$10.25M | $283.0K | $64.0K | $48.0K | $10.05M | $0 | $5.0K |
| Share repurchases | - | - | - | - | - | - | $0 | $0 | - | - | $0 | $0 |
| Stock-based compensation | $172.0K | $172.0K | $162.0K | $24.0K | $107.0K | $3.33M | $628.0K | $365.0K | $379.0K | $381.0K | $688.0K | $955.0K |
Key ratios
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth, YoY | - | - | - | - | - | - | - | - | - | - | -100.0% | -100.0% |
| Current ratio | 33.15 | 39.03 | 16.01 | 41.78 | 40.16 | 29.15 | 11.56 | 11.57 | 11.13 | 12.03 | 33.07 | 38.61 |
Source: XBRL data XBiotech Inc. files with the SEC, latest filing dated Aug 13, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures are as filed. The filings show no stock split in these periods.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
XBIT peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| XBIT | - | - | -$45.13M | - | $58.2M |
| REGN | $16.90B | +18.6% | $4.82B | 28.5% | $95.17B |
| VIR | $302.80M | +1696.0% | -$184.79M | -61.0% | $2.34B |
| ABCL | $67.86M | +92.1% | -$148.29M | -218.5% | $4.05B |
| AMGN | $38.90B | +8.2% | $9.39B | 24.1% | $251.65B |
| XNCR | $200.49M | +33.5% | -$117.86M | -58.8% | $2.90B |
| MGNX | $167.67M | +11.7% | -$14.59M | -8.7% | $149.1M |
XBIT FAQ
5 questionsIs XBIT profitable?
No. XBiotech Inc. reported a net loss of $45.13M for the twelve months ended Jun 30, 2026.How much cash and debt does XBIT have?
XBiotech Inc. reported $109.53M in cash and cash equivalents on its most recent balance sheet in SEC filings.What is XBIT free cash flow?
XBiotech Inc. generated -$40.84M of free cash flow for the twelve months ended Jun 30, 2026, which is operating cash flow of -$40.70M less capital expenditures.When did XBIT last report financial results?
The latest statements here come from XBiotech Inc.'s 10-Q filed on Aug 13, 2026, covering the period ended Jun 30, 2026.Where does this XBIT financial data come from?
Quantisnow builds these statements from the structured XBRL data XBiotech Inc. files with the SEC. It is provided for information only and is not investment advice.